In the case of BiKEs, one of the variable antibody domains recognizes CD16 and the other a targeted tumor antigen (242), whereas, TriKEs, in addition to these two domains, have an interleukin 15 (IL15) element that connects the two different antibody domains. The gene discussed is FCGR3A; the disease is neoplasm.